Benzinga · Mar 3, 2026
SO
NASDAQ · SOPH
SOPHiA GENETICS S.A.
Healthcare · Medical - Healthcare Information Services
$7.11
Down-$0.52 (-6.82%)
Updated Nov 3, 2026, 8:07 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 321.51M
- P/E ratio
- -4.39
- Dividend yield
- 0.00%
- 52-week range
- $4.28 – $8.98
- Volume
- 407.29K
- Avg. volume
- 114.15K
Price performance · SOPH
SOPH price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
SOPH closed at $7.11 after 21 trading sessions, down 13.29% for the selected period.
- Last close
- $7.11
- Period change
- -13.29%
- Period low
- $6.49
- Period high
- $8.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $7.66 | $7.685 | $7.03 | $7.11 | 407.29K |
| Oct 30, 2026 | $7.95 | $7.999 | $7.35 | $7.63 | 379.21K |
| Oct 29, 2026 | $7.83 | $7.99 | $7.6344 | $7.97 | 208.06K |
| Oct 28, 2026 | $7.55 | $7.88 | $7.51 | $7.87 | 285.14K |
| Oct 27, 2026 | $7.55 | $7.76 | $7.51 | $7.54 | 303.81K |
| Oct 26, 2026 | $7.40 | $7.53 | $7.2501 | $7.52 | 261.14K |
| Oct 23, 2026 | $6.99 | $7.4064 | $6.90 | $7.35 | 455.64K |
| Oct 22, 2026 | $7.27 | $7.38 | $6.97 | $7.05 | 353.2K |
| Oct 21, 2026 | $6.99 | $7.43 | $6.98 | $7.35 | 591.93K |
| Oct 20, 2026 | $6.49 | $6.97 | $6.39 | $6.93 | 639.61K |
| Oct 19, 2026 | $6.83 | $6.95 | $6.42 | $6.49 | 510.91K |
| Oct 16, 2026 | $7.34 | $7.48 | $6.72 | $6.73 | 917.65K |
| Oct 15, 2026 | $7.00 | $7.44 | $6.83 | $7.29 | 1.76M |
| Oct 14, 2026 | $7.06 | $7.205 | $7.01 | $7.06 | 377.45K |
| Oct 13, 2026 | $7.20 | $7.325 | $7.05 | $7.09 | 271.22K |
| Oct 12, 2026 | $7.44 | $7.69 | $7.01 | $7.22 | 478.89K |
| Oct 9, 2026 | $7.32 | $7.4636 | $7.07 | $7.41 | 328.12K |
| Oct 8, 2026 | $7.15 | $7.40 | $6.8405 | $7.30 | 499.92K |
| Oct 7, 2026 | $7.26 | $7.3696 | $7.08 | $7.15 | 432.83K |
| Oct 6, 2026 | $8.40 | $8.564 | $7.335 | $7.38 | 929.1K |
| Oct 5, 2026 | $8.10 | $8.34 | $7.90 | $8.20 | 1.18M |
Latest SOPH news
The latest Smart Investors Daily articles mentioning SOPH.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SOPH research
Overview
Company profile and research snapshot.
Company profile
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $5.33
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 5, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 5, 2026 | BTIG | Buy | — |
| Jul 20, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 15, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Mar 3, 2026
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
ChartMill · Mar 3, 2026
SOPHiA GENETICS SA (NASDAQ:SOPH) Reports Mixed Q4 2025 Results with Revenue Beat and EPS Miss
SOPHiA GENETICS reports Q4 2025 revenue beat but wider-than-expected loss, highlighting growth in AI-driven genomic analysis as path to profitability continues.
SeekingAlpha · Mar 3, 2026
SOPHiA GENETICS SA 2025 Q4 - Results - Earnings Call Presentation
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
